Results for tag: "Recombinant Protein Therapeutics CDMO"

Recombinant Protein Therapeutics CDMO (Contract Development and Manufacturing Organization) is a specialized service provider that assists in the development and manufacturing of recombinant proteins for drug discovery. These proteins are produced through recombinant DNA technology, which involves the insertion of a gene into a host organism to produce a desired protein. CDMOs provide a range of services, including process development, analytical testing, and manufacturing of recombinant proteins. They also provide support for regulatory compliance and quality assurance. Recombinant protein therapeutics are used in drug discovery to identify and develop new treatments for diseases. They are also used to develop biologics, which are drugs derived from living organisms. The use of recombinant proteins in drug discovery has enabled the development of treatments for a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. Companies in the Recombinant Protein Therapeutics CDMO market include Lonza, Boehringer Ingelheim, Merck KGaA, and Fujifilm Diosynth Biotechnologies. Show Less Read more